These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [The immunosuppressive agents. 3. The immunosuppressive agents in hematology]. Meshaka G; Jacquillat C; Sultan Y Presse Med (1893); 1967 Jul; 75(32):1653-5. PubMed ID: 6067478 [No Abstract] [Full Text] [Related]
43. Relapse following treatment withdrawal in autoimmune chronic active hepatitis. McCullough AJ; Czaja AJ Hepatology; 1984; 4(4):747-8. PubMed ID: 6745867 [No Abstract] [Full Text] [Related]
44. Perspectives of immunosuppressive therapy in human immunologic diseases. Cruchaud A Folia Allergol (Roma); 1970; 17(4):447-8. PubMed ID: 5458014 [No Abstract] [Full Text] [Related]
45. [Immunosuppressive therapy - review of up-to-date experience in the world and in our country]. Jovanović D Med Arh; 1976; 30(5):307-15. PubMed ID: 1018520 [No Abstract] [Full Text] [Related]
46. [Immunosuppressive effect of cytostatics in the clinic]. Gerhartz H Schweiz Rundsch Med Prax; 1970 Jul; 59(29):1049-52. PubMed ID: 5512654 [No Abstract] [Full Text] [Related]
47. Practical use of immunosuppressive drugs in autoimmune rheumatic diseases. De Jesus A; Talal N Crit Care Med; 1990 Feb; 18(2 Suppl):S132-7. PubMed ID: 2298028 [TBL] [Abstract][Full Text] [Related]
48. Immunosuppressive therapy in management of non-malignant disease. Fennelly JJ; Fitzgerald MX; Fitzgerald O J Ir Med Assoc; 1970 Apr; 63(394):141-6. PubMed ID: 5418154 [No Abstract] [Full Text] [Related]
49. [Immunosuppressive treatments of patients with autoimmune disorders]. Wasastjerna C Nord Med; 1967 Nov; 78(45):1469-75. PubMed ID: 6070858 [No Abstract] [Full Text] [Related]
50. [Immunosuppressive therapy and its side-effects]. Scheiffarth F Clin Ter; 1971 Jul; 57(6):493-503. PubMed ID: 5136486 [No Abstract] [Full Text] [Related]
51. [Terebrant and recurring herpes and zona in the course of hemopathies (treated with immunosuppressive agents)]. Laugier P; Orusco M J Med Lyon; 1972 Sep; 53(232):1105-7. PubMed ID: 4344441 [No Abstract] [Full Text] [Related]
52. [The use of immunosuppressive agents for children]. Lévêque B; Donea M Ann Pediatr (Paris); 1967 Mar; 14(3):248-57. PubMed ID: 5614549 [No Abstract] [Full Text] [Related]
53. [Immunologic and pharmacological principles for the use of immunosuppressive drugs in autoimmune diseases]. Floersheim GL Schweiz Med Wochenschr; 1970 Dec; 100(52):2241-7. PubMed ID: 4946978 [No Abstract] [Full Text] [Related]
54. [Mechanism of action of immunosuppressive drugs]. Dimitriu CG; Zeana C Med Interna (Bucur); 1972 Aug; 24(8):977-83. PubMed ID: 5080894 [No Abstract] [Full Text] [Related]
56. Hematologic effects of androgens revisited: an alternative therapy in various hematologic conditions. Besa EC Semin Hematol; 1994 Apr; 31(2):134-45. PubMed ID: 8066470 [No Abstract] [Full Text] [Related]
57. Recent advances in the treatment of autoimmune mucocutaneous blistering diseases. Ahmed AR Int J Periodontics Restorative Dent; 2007 Aug; 27(4):309-10. PubMed ID: 17726986 [No Abstract] [Full Text] [Related]
58. [Treatment of immunological disorders in digestive diseases]. Fodor O; Nicoară G Stud Cercet Med Interna; 1969; 10(4):287-96. PubMed ID: 4905681 [No Abstract] [Full Text] [Related]
59. Childhood vitiligo and tacrolimus: immunomodulating treatment for an autoimmune disease. Plettenberg H; Assmann T; Ruzicka T Arch Dermatol; 2003 May; 139(5):651-4. PubMed ID: 12756103 [No Abstract] [Full Text] [Related]